- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
Latisse summit introduces physicians to eyelash-growing product
National report ? Allergan has officially launched its eyelash-growing product Latisse (bimatoprost ophthalmic solution 0.03 percent) to doctors who may be interested in prescribing it, according to Ophthalmology Times.
National report
- Allergan has officially launched its eyelash-growing product Latisse (bimatoprost ophthalmic solution 0.03 percent) to doctors who may be interested in prescribing it, according to Ophthalmology Times.
In early April, Allergan beamed a satellite program, “The Latisse Summit,” to more than 1,000 physicians in 34 cities across the country.
Latisse, indicated for treatment of hypotrichosis of the eyelashes, increases growth, length, thickness and darkness. Though the exact mechanism of action is unknown, researchers suspect Latisse increases the percentage of eyelash hairs during the growth phase and increases the duration of the phase, according to the article.
Efficacy was tested in a phase 3 multicenter, double-blind, randomized, placebo-controlled clinical trial in which 137 patients received active treatment and 141 received vehicle alone for four months, followed by one month withdrawal. Researchers found that those treated with the active drug had a 25 percent increase in eyelash length compared to those receiving vehicle.
